Worth reading
60In focus
Scored from 3 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Summary of Q&ASecond quarter of the fiscal year ending September 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit marginOperating profit margin was described as having improved sharply, but the margin and year-on-year figures were not disclosed
What the company explained in this material
Key points of the Q&AKey questions raised by investors at the briefing and the company's answers
- The improvement in operating profit margin was due to the higher sales mix of the medical support business and optimization of advertising investment in the D2C business. Although short-term fluctuations are possible, the company aims to achieve a higher profit level than previously over the medium to long term.
- The full-year plan was calculated based on progress to date and confirmed projects, with synergies with SBC Medical Group incorporated conservatively.
- Growth drivers for the medical support business include an increase in the number of affiliated clinics, a utilization rate of more than 60%, post-implementation support, and collaboration with SBC Medical Group.
- The D2C business is not being downsized; its role is being redefined, with priority given to capital efficiency and profit generation rather than sales scale.
- Regarding becoming part of the SBC group, the company places importance on independence, the interests of minority shareholders, and governance, while recognizing the significant benefits of accelerating growth.
- Intellectual property is positioned as a growth investment that contributes not only to licensing revenue but also to creating barriers to entry, avoiding price competition, strengthening partnership advantages, and expanding overseas.
- There are no specific M&A transactions at present, but potential synergies involving technology, medical networks, and overseas expansion will continue to be examined.
- Future growth drivers are the continued growth of the medical support business, synergies with SBC Medical Group, and the horizontal expansion of services. Over the medium to long term, regenerative medicine, new products, overseas expansion, and medical-related businesses will also be areas of focus.
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Calculated based on progress to date and projects confirmed as of the current point. Synergies with SBC Medical Group have been incorporated conservatively, but the numerical assumptions were not disclosedNew initiatives
Transform the business structure toward the healthcare and regenerative medicine fields centered on the medical support business, redefine the D2C business as a cash-generation function, collaborate with SBC Medical Group, and use intellectual property as a growth investmentKey KPIsA metric the company considers important as a management benchmark.
- Utilization rateMore than 60%
- Number of affiliated clinics
- Number of units processed
Financial targets
ROE was described as very high, but the target and actual figures were not disclosedMarket Size / Share
The potential for market growth was described qualitatively, but figures for market size and market share were not disclosed| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Second quarter of the fiscal year ending September 2026 |
| Operating profit margin | Operating profit margin was described as having improved sharply, but the margin and year-on-year figures were not disclosed |
| Key KPIs | Indicator name Utilization rate / Value More than 60% / Year on year against the same period last year Not disclosed, Indicator name Number of affiliated clinics / Value Not disclosed / Year on year against the same period last year Not disclosed, Indicator name Number of units processed / Value Not disclosed / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | Calculated based on progress to date and projects confirmed as of the current point. Synergies with SBC Medical Group have been incorporated conservatively, but the numerical assumptions were not disclosed |
| Financial targets | ROE was described as very high, but the target and actual figures were not disclosed |
| Market Size / Share | The potential for market growth was described qualitatively, but figures for market size and market share were not disclosed |
| Key points of the Q&A | The improvement in operating profit margin was due to the higher sales mix of the medical support business and optimization of advertising investment in the D2C business. Although short-term fluctuations are possible, the company aims to achieve a higher profit level than previously over the medium to long term., The full-year plan was calculated based on progress to date and confirmed projects, with synergies with SBC Medical Group incorporated conservatively., Growth drivers for the medical support business include an increase in the number of affiliated clinics, a utilization rate of more than 60%, post-implementation support, and collaboration with SBC Medical Group., The D2C business is not being downsized; its role is being redefined, with priority given to capital efficiency and profit generation rather than sales scale., Regarding becoming part of the SBC group, the company places importance on independence, the interests of minority shareholders, and governance, while recognizing the significant benefits of accelerating growth., Intellectual property is positioned as a growth investment that contributes not only to licensing revenue but also to creating barriers to entry, avoiding price competition, strengthening partnership advantages, and expanding overseas., There are no specific M&A transactions at present, but potential synergies involving technology, medical networks, and overseas expansion will continue to be examined., Future growth drivers are the continued growth of the medical support business, synergies with SBC Medical Group, and the horizontal expansion of services. Over the medium to long term, regenerative medicine, new products, overseas expansion, and medical-related businesses will also be areas of focus. |
| New initiatives | Transform the business structure toward the healthcare and regenerative medicine fields centered on the medical support business, redefine the D2C business as a cash-generation function, collaborate with SBC Medical Group, and use intellectual property as a growth investment |
Items this document does not state (22)
Net SalesOperating profitOrdinary incomeNet incomeGross Profit MarginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The medical support business generates recurring revenue, offers high value added, and has a high contribution margin through the use of the existing network. In the D2C business, advertising investment is being optimized and operations are being shifted toward a profit-focused model.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.